A Company Asked the FDA to Ban Most Ketamine. The Public Docket Has Two Comments
A drug company has asked the Food and Drug Administration to ban ketamine products made with a common preservative. The same company has since won FDA approval for a version without the preservative, on October 30, 2026. The request surfaced in a New York Times report on Monday. The petition is public, the docket is still open, and two comments have been filed on it in thirteen months.
The cost of the drug is one line. The rest of the cost structure is negotiable today. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The filing | Citizen Petition from NRx Pharmaceuticals, docket FDA-2025-P-3577, received September 4, 2025 |
| What it asks | That FDA ban all products containing ketamine combined with benzethonium chloride |
| Who benefits | NRx won FDA approval for its preservative-free ketamine on October 30, 2026 |
| The evidence | NRx’s chief executive acknowledged to the Times there is no human data tying the preservative to harm |
| Comments filed | Two have been published since the docket opened |
| Status | Open, and marked as allowing late comments |
What the Petition Actually Asks For
The docket title is not ambiguous. It reads, requests that the FDA ban all products containing ketamine combined with benzethonium chloride.
Benzethonium chloride, or BZT, is a preservative. We checked the FDA’s own label directory. Of the 12 ketamine hydrochloride injection labels listed there, 11 contain it. That includes Ketalar and generics from Hospira, Fresenius Kabi, Sagent, Civica and Gland Pharma. The one exception is a Baxter single-dose pre-filled syringe. Every label that identifies itself as a multi-dose vial carries the preservative. That is what gives the request its reach.
It was received on September 4 last year and posted the following day. The agency’s drug evaluation center has it docketed as a citizen petition.
The Company Asking Also Sells the Alternative
NRx Pharmaceuticals filed the petition. NRx also sought approval for a product of its own, which FDA cleared on October 30, 2026. That is generic ketamine in a vial that stays sterile without a preservative.
So one filing would remove the existing supply from the market. The other would put the company’s own product in its place.
The Times reports NRx has already ordered five million doses ahead of a decision. Executives would not say what they plan to charge.
What the Evidence Looks Like
NRx chief executive Jonathan Javitt addressed the evidence directly. He acknowledged the lack of data tying the preservative in ketamine to harm in humans.
His argument rests on precedent elsewhere. FDA barred the compound from over-the-counter hand sanitizers in 2019, and manufacturers phased it out of most eye products.
Critics in the piece make the opposite case. The preservative has been in medicines for more than half a century without reported problems.
Christian Yavorsky worked on the trials behind Spravato. He said patients do not receive enough doses for the preservative to cause harm. A board member of the American Society of Ketamine Physicians called the effort, in his words, unethical and cash-grabby.
Two Comments in Thirteen Months
We went to the docket to see what the field had said. The answer is almost nothing.
Two comments have been published since it opened. One is anonymous. The other came from a law firm acting for another company. It runs to seven attachments, including the brand ketamine label and the FDA order NRx cites.
That is the entire published record. The industry behind it runs to roughly 1,600 ketamine clinics, by our own directory count.
One company has made its case in detail. The providers who would absorb the consequences have not.
What a Ban Would Cost a Clinic
Generic ketamine costs roughly a dollar a dose. That is the number a ban would replace with an unknown one.
The Times puts the ketamine market at about $750 million. It notes the drug is made mostly in China and India, with shortages already intermittent.
That supply chain is already thin. Removing the dominant formulation from it is not the same as adding a competitor to it.
Nothing here is decided. A citizen petition is a request, and FDA can deny it. But the cost side of a clinic is a bad thing to learn about late. It is the same reason we keep a running calendar of regulatory deadlines.
The Window Is Still Open
The docket status reads open, and it is marked as allowing late comments.
Anyone can file one. It takes a form on the federal docket, and the comment becomes part of the public record the agency reviews.
A clinician buys this drug every week. That person knows things about handling, dosing and shortages that a sponsor’s petition does not contain.
The docket is FDA-2025-P-3577, and comments go through the comment form on that petition.
A Decision Measured in Weeks
NRx told the Times it expected a decision in early November. The approval arrived on October 30. The petition sits on its own track, and FDA does not discuss pending applications.
What is certain is the timing. Both items are live now, and the comment record is two entries long.
Clinics comparing notes can start with our directory of verified ketamine clinics.
The FDA has since acted on the other half. It approved a preservative-free ketamine while the ban petition stayed pending.
This article is for informational purposes and is not legal or medical advice. Petition and docket details come from the public record on regulations.gov, read October 21, 2026. Statements from company executives and clinicians are as reported by the New York Times.

Kamee Witts
October 25, 2026 at 3:38 pmThis is incredibly concerning and dangerous. I have owned my ketamine clinic for 7 yrs and it’s been challenging to obtain ketamine at times to care for our patients with severe Depression and PTSD. Thank you for bringing attention to this. As a psychiatric nurse practitioner who provides ketamine treatment, I am deeply concerned about what this proposal could mean for patients who rely on it to stay mentally well.
These are real people whose stability, relationships, and ability to function could be jeopardized by interrupted treatment or higher costs. The potential harm of losing access needs to be taken just as seriously as any concern about a preservative.
Ketamine has been studied for decades, and, as the article explains, this preservative has been included in many ketamine formulations over that time. The article also indicates that there is no evidence showing that the preservative has caused harm in the formulations at issue. If that is the case, removing widely used formulations based on an unsupported safety concern would be difficult to justify. Any regulatory action should be grounded in rigorous, independent evidence and not speculation. This is just greed.
No pharmaceutical company should be allowed to use regulatory action to create a monopoly over an essential medication. Restricting affordable options while financially benefiting from the alternative raises serious concerns about whose interests are being served.
Patient safety includes continuity of care and affordability. Patients who have finally found something that helps them deserve to have their voices heard before decisions are made that could take that stability away.
Kamee
Tara Dillon
October 25, 2026 at 3:51 pmThis is a brazen money grab that will cause significant harm to the large cohort of patients who benefit from current, equally-effective-and-far-less-costly ketamine treatment. Absolutely monstrous.
Randy Black
October 25, 2026 at 4:34 pmMany of us rely on this medication and don’t need a more expensive version to be the only version raising the already expensive prices of infusions. Just a money play by a greedy Pharma company.
Valarie Powlina
October 25, 2026 at 7:56 pmBy banning the present status quo ket@mine that’s in current use for infusions, it will become harder and more expensive to secure affordable, quick, infusions. With only one type of K allowed, patients may end up on wait lists or unable to afford this.
Tonya neuman
October 25, 2026 at 10:05 pmThis would be detrimental to
People who have to pay out of pocket. Insurance doesn’t cover care and to get any sort of normalcy, this is what is helping.
Kelly Cowley
October 26, 2026 at 12:00 amPlease don’t support this change this medication helps save so many lives we should be eitking towards insurance coverage to provide this fir everyone.
Lindsay Miller
October 26, 2026 at 4:51 pmKetamine is lifesaving for people like me with CRPS. It’s not covered by insurance. Do not make it more difficult for us to get the infusions that make life more bearable, please. Things are already hard and expensive enough. Please don’t make them harder and more expensive.
Theresa Ripski
October 26, 2026 at 7:36 pmHaving just one option should never be an answer. It causes higher prices, no competition, terrible problems if the single source has a production issue, contamination, etc
Kirsten Sultemeier
October 29, 2026 at 4:23 amThis is blatant greed. As a USMC veteran with CRPS & PTSD, I have had ketamine treatments for 13 years. They work.
There is no need to create a costly medication and force doctors to use it.
It’s time to take greed out of our medial system.